The following transcript has been edited for clarity:

Diana V. Do, MD: Hi, I’m joined by Frank Brodie, MD, MBA, from the University of California, San Francisco. You gave a great presentation about a prosthetic capsular bag (LensOne; Long Bridge Medical) today at Clinical Trials at the Summit. Give us the key take-home points.

Frank Brodie, MD, MBA: Thanks so much, Diana. It’s a pleasure to be here. The big thing we were trying to present today was not only the safety and efficacy profile, which we’ve shown before as far as refractive outcomes of the prosthetic capsular bag and the long-term safety follow-up, but also now we’re showing for the first time the minimal amount of tilt and decentration of lenses in the prosthetic bag. It’s not only better than all the secondary lens techniques out there that we see, but it’s comparable to in-the-bag phaco, which is really exciting.

Dr. Do: What’s the future trajectory of this prosthetic capsular bag? When can we get it actually in surgeons’ hands?

Dr. Brodie: Oh, that’s the million-dollar question. We’re excited to launch the GOLDEN GATE trial. We’ll start this fall. It’s going to be a multicenter prospective US pivotal trial, so we’re very excited to be starting that soon.

Dr. Do: Thank you so much for that information, and we look forward to hearing more from you in the future.

Dr. Brodie: Thanks so much. RP